The Latest

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    London-based Charm Therapeutics closed a $80 million Series B round this week to fund development of its drug for acute myeloid leukemia. It’s planning to enter the clinic in the first quarter of 2026.

    Updated Sept. 2, 2025
  • A person stands next to a table where another person sits.
    Image attribution tooltip
    Courtesy of Treeline Biosciences
    Image attribution tooltip
    Emerging biotech

    Secretive startup Treeline unveils first clinical candidates, $200M in new funding

    The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip
    China competition

    Novartis licenses RNA drugs in deal with China-based Argo

    The alliance, which could be worth more than $5 billion, is one of a handful of deals Novartis has struck with China-based biotechs in recent years. 

  • The exterior of Ionis Pharmaceuticals' headquarters in Carlsbad, California.
    Image attribution tooltip
    Courtesy of Ionis Pharmaceuticals
    Image attribution tooltip

    Ionis looks to expand use of lipid-lowering drug after trial hits goal

    Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.

  • A neurodegenerative disease concept illustration
    Image attribution tooltip
    image_jungle via Getty Images
    Image attribution tooltip
    Brain drug revival

    Novartis thinks Arrowhead brain drug can succeed where others couldn’t

    A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat diseases like Parkinson’s.

  • A person in a blue suit gestures while seated at a conference table.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    The Trump administration is remaking HHS. Track the changes here.

    HHS is ousting CDC Director Susan Monarez just weeks after her confirmation, although her lawyers say the firing is invalid. Three other top CDC officials resigned in protest.

    Updated Aug. 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Amgen to invest $600M in new US center; Sanofi drug for ITP approved

    The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.

  • A sign bearing the logo for the Centers for Disease Control and Prevention stands outside of an office building.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    CDC panel to discuss COVID, hepatitis B shots in meeting next month

    A federal register notice confirmed dates for the anticipated advisory meeting, which will follow an FDA decision to narrow COVID boosters' approval and comes as CDC leadership is in turmoil.

  • A 3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Novo strikes RNA drug deal with startup Replicate

    The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly says breast cancer drug extended survival in study

    Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    MannKind will pay about $300 million upfront to acquire scPharmaceuticals and its diuretic for chronic kidney disease and heart failure.

    Updated Aug. 25, 2025
  • Boxes of COVID-19 vaccines from Pfizer and Moderna sit side by side.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip
    Vaccines

    FDA approves updated COVID boosters, but narrows use

    While the agency cleared vaccines from Pfizer, Moderna and Novavax broadly in older adults, it restricted eligibility in younger people to those with underlying health conditions.

    Updated Aug. 27, 2025
    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Amylyx drug comes up short; Sanofi names new CMO

    AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T

    The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial. 

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

    Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

    Updated Aug. 26, 2025
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Schizophrenia drug developer LB Pharmaceuticals on Friday filed plans for an initial public offering, after a six-month stretch with few substantive biotech offerings.

    Updated Aug. 25, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly to submit obesity pill after hitting goal in third late-stage trial

    In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Why an FDA decision on Stealth’s Barth drug could ripple through the rare disease field

    Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could carry broader consequences.

  • Image of a brain in purple outline with red details.
    Image attribution tooltip
    Naeblys via Getty Images
    Image attribution tooltip

    AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug

    The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.

  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Vaccines

    FDA suspends license for Valneva’s chikungunya shot

    The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to conclude the vaccine is no longer safe for its intended use.

    FDA
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations. 

    Updated April 9, 2025
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Image attribution tooltip

    Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales

    An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.

  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA’s new accelerated pathway may open pharma up to risks, as well as benefits

    Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty to the approval process.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    FDA cancels adcomm on Biohaven drug; Catalent lays off staff

    Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff at a gene therapy facility.

  • A photo of Gilead's cell therapy manufacturing facility in Frederick, Maryland
    Image attribution tooltip
    Courtesy of Gilead
    Image attribution tooltip
    Emerging biotech

    Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

    The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.